Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA363 for Chronic Discogenic Low Back Pain
2019-004943-54Phase 2Active
- Sponsor
- Stayble Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lactic acid in discogenic back pain and lumbodynia (LBP) (3 arms), sponsored by Stayble Therapeutics. Primary endpoint: Primary efficacy endpoint. Started Mar 2020; status: active.
02
Drugs
lactic acid
03
Conditions
discogenic back painlumbodynia (LBP)
Beyond the preview
Go deeper on 2019-004943-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004943-54.